---
title: "12 Health Care Stocks Moving In Tuesday's Pre-Market Session"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292623389.md"
description: "In Tuesday's pre-market session, several healthcare stocks showed significant movement. NextCure surged 305.5% to $8.84, while Shuttle Pharmaceuticals rose 72.93%. Other gainers included Picard Medical, Ensysce Biosciences, Bluejay Diagnostics, and Polyrizon. On the losing side, Matinas BioPharma dropped 19.8%, followed by declines in Evotec, XTL Biopharmaceuticals, Trevi Therapeutics, China Pharma Holding, and CNS Pharmaceuticals."
datetime: "2026-07-14T12:05:32.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292623389.md)
  - [en](https://longbridge.com/en/news/292623389.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292623389.md)
generator: "portal-rs"
---

# 12 Health Care Stocks Moving In Tuesday's Pre-Market Session

### Gainers

-   **NextCure** (NASDAQ:NXTC) shares rose 305.5% to $8.84 during Tuesday's pre-market session. The market value of their outstanding shares is at $7.8 million.
-   **Shuttle Pharmaceuticals** (NASDAQ:SHPH) stock moved upwards by 72.93% to $5.12. The market value of their outstanding shares is at $1.7 million.
-   **Picard Medical** (AMEX:PMI) shares increased by 23.43% to $0.18. The company's market cap stands at $14.6 million.
-   **Ensysce Biosciences** (NASDAQ:ENSC) stock rose 16.15% to $0.32. The company's market cap stands at $4.2 million.
-   **Bluejay Diagnostics** (NASDAQ:BJDX) shares rose 14.75% to $1.4. The market value of their outstanding shares is at $1.2 million.
-   **Polyrizon** (NASDAQ:PLRZ) stock rose 14.35% to $15.85. The company's market cap stands at $28.8 million.

### Losers

-   **Matinas BioPharma Hldgs** (AMEX:MTNB) shares decreased by 19.8% to $0.38 during Tuesday's pre-market session. The market value of their outstanding shares is at $3.0 million.
-   **Evotec** (NASDAQ:EVO) stock fell 13.59% to $2.1. The company's market cap stands at $863.8 million.
-   **XTL Biopharmaceuticals** (NASDAQ:XTLB) shares decreased by 12.16% to $2.53. The market value of their outstanding shares is at $7.0 million.
-   **Trevi Therapeutics** (NASDAQ:TRVI) shares fell 12.11% to $14.52. The market value of their outstanding shares is at $2.3 billion.
-   **China Pharma Holding** (AMEX:CPHI) stock declined by 11.61% to $0.55. The company's market cap stands at $25.3 million.
-   **CNS Pharmaceuticals** (NASDAQ:CNSP) shares declined by 11.6% to $4.5. The market value of their outstanding shares is at $7.4 million. **See Also:** www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

### Related Stocks

- [BJDX.US](https://longbridge.com/en/quote/BJDX.US.md)
- [PLRZ.US](https://longbridge.com/en/quote/PLRZ.US.md)
- [ENSC.US](https://longbridge.com/en/quote/ENSC.US.md)
- [EVO.US](https://longbridge.com/en/quote/EVO.US.md)
- [SHPH.US](https://longbridge.com/en/quote/SHPH.US.md)
- [PMI.US](https://longbridge.com/en/quote/PMI.US.md)
- [XTLB.US](https://longbridge.com/en/quote/XTLB.US.md)
- [CNSP.US](https://longbridge.com/en/quote/CNSP.US.md)
- [NXTC.US](https://longbridge.com/en/quote/NXTC.US.md)
- [CPHI.US](https://longbridge.com/en/quote/CPHI.US.md)
- [TRVI.US](https://longbridge.com/en/quote/TRVI.US.md)
- [EVT.DE](https://longbridge.com/en/quote/EVT.DE.md)
- [MTNB.US](https://longbridge.com/en/quote/MTNB.US.md)
- [ENSCW.US](https://longbridge.com/en/quote/ENSCW.US.md)

## Related News & Research

- [Ensysce Biosciences raises over $21 million in Series C preferred stock private placement](https://longbridge.com/en/news/296829867.md)
- [Ensys receives Nasdaq compliance notices but cleared equity rule; granted bid-price extension](https://longbridge.com/en/news/296956235.md)
- [CNS Pharmaceuticals Participates in the Virtual Investor "Why Now" On-Demand Conference  | CNSP Stock News](https://longbridge.com/en/news/297192799.md)
- [Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Consensus Recommendation of "Buy" from Analysts](https://longbridge.com/en/news/296880224.md)
- [Trevi Therapeutics to present Phase 2b CORAL nalbuphine ER quality-of-life data in IPF cough at ERS 2026](https://longbridge.com/en/news/297037112.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**